|
|
Next Article 
Bleeding and thrombosis in the myeloproliferative disorders
AI Schafer
Bleeding and thrombosis are major causes of morbidity and mortality in
patients with myeloproliferative disorders. The significance of
uncontrolled polycythemia as a risk factor for thrombosis in these patients
has been established. However, the role of thrombocytosis in the
pathogenesis of hemostatic complications remains controversial.
Abnormalities of platelet function and prolongation of the bleeding time
occur in a highly variable number of cases. Specific platelet defects that
have been identified in the myeloproliferative defects include abnormal
platelet morphology, acquired storage pool disease, platelet membrane
abnormalities, and abnormal arachidonic acid metabolism. Causal
relationships between any of these specific abnormalities and either
bleeding or thrombosis have not been clearly established. The therapeutic
efficacy of myelosuppression to reduce the platelet count in patients with
thrombocytosis and the role of antiplatelet drugs in the myeloproliferative
disorders are controversial issues.
Volume 64,
Issue 1,
pp. 1-12,
07/01/1984
Copyright © 1984 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M.-P. Wautier, W. El Nemer, P. Gane, J.-D. Rain, J.-P. Cartron, Y. Colin, C. Le Van Kim, and J.-L. Wautier
Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin {alpha}5 chain and Lu/BCAM
Blood,
August 1, 2007;
110(3):
894 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. I. Schafer
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Blood,
June 1, 2006;
107(11):
4214 - 4222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Kaftan, O. S. Balcik, H. Cipil, G. Ozet, N. Bavbek, A. Kosar, and S. Dagdas
Plasma Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Primary and Secondary Thrombocytosis
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2005;
11(4):
449 - 454.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Birdane, I. C. Haznedaroglu, N. Bavbek, A. Kosar, Y. Buyukasik, O. Ozcebe, S. V. Dundar, and S. Kirazli
The Plasma Levels of Prostanoids and Plasminogen Activator Inhibitor-1 in Primary and Secondary Thrombocytosis
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2005;
11(2):
197 - 201.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini, M. Balicco, S. Manarini, G. Finazzi, C. Cerletti, and T. Barbui
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
Blood,
December 15, 2000;
96(13):
4261 - 4266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Randi, C. Rossi, F. Fabris, L. Menapace, and A. Girolami
State-of-the-Art Review : Aspirin Seems as Effective as Myelosuppressive Agents in the Prevention of Rethrombosis in Essential Thrombocythemia
Clinical and Applied Thrombosis/Hemostasis,
April 1, 1999;
5(2):
131 - 135.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Egermayer, G I. Town, and A. J Peacock
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension
Thorax,
February 1, 1999;
54(2):
161 - 168.
[Full Text]
|
|
|
|
|
|
|
C. N. Harrison, R. E. Gale, S. J. Machin, and D. C. Linch
A Large Proportion of Patients With a Diagnosis of Essential Thrombocythemia Do Not Have a Clonal Disorder and May Be at Lower Risk of Thrombotic Complications
Blood,
January 15, 1999;
93(2):
417 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. O. Yildiz, B. Oran, Y. Buyukasik, b. C. Haznedaroglu, S. Cekirge, and S. Kirazli
Acute Budd-Chiari Syndrome Associated with Activated Protein C Resistance During Intravenous Anticoagulant Treatment
Clinical and Applied Thrombosis/Hemostasis,
July 1, 1998;
4(3):
220 - 223.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. L. Randi, F. Fabris, G. Cella, C. Rossi, and A. Girolami
Cerebral Vascular Accidents in Young Patients with Essential Thrombocythemia: Relation with Other Known Cardiovascular Risk Factors
Angiology,
June 1, 1998;
49(6):
477 - 481.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. M. Rinder, J. E. Schuster, C. S. Rinder, C. Wang, H. J. Schweidler, and B. R. Smith
Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis
Blood,
February 15, 1998;
91(4):
1288 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S Markus and H. Hambley
Neurology and the blood: haematological abnormalities in ischaemic stroke
J. Neurol. Neurosurg. Psychiatry,
February 1, 1998;
64(2):
150 - 159.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Horikawa, I. Matsumura, K. Hashimoto, M. Shiraga, S. Kosugi, S. Tadokoro, T. Kato, H. Miyazaki, Y. Tomiyama, Y. Kurata, et al.
Markedly Reduced Expression of Platelet c-mpl Receptor in Essential Thrombocythemia
Blood,
November 15, 1997;
90(10):
4031 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Najean and J.-D. Rain
Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years
Blood,
November 1, 1997;
90(9):
3370 - 3377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Osselaer, J. Jamart, and J.-M. Scheiff
Platelet distribution width for differential diagnosis of thrombocytosis
Clin. Chem.,
June 1, 1997;
43(6):
1072 - 1076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Gabazza, H. Takeya, H. Deguchi, O. Taguchi, H. Wada, J. Nishioka, Hong Zhou, and K. Suzuki
Acquired Activated Protein C Resistance in Patients with Lupus Anticoagulant and Essential Thrombocythemia
Clinical and Applied Thrombosis/Hemostasis,
April 1, 1997;
3(2):
119 - 123.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Najean and J.-D. Rain
Treatment of Polycythemia Vera: Use of 32P Alone or in Combination With Maintenance Therapy Using Hydroxyurea in 461 Patients Greater Than 65 Years of Age
Blood,
April 1, 1997;
89(7):
2319 - 2327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Arboix, C. Besses, P. Acin, J. B. Massons, L. Florensa, M. Oliveres, and J. Sans-Sabrafen
Ischemic Stroke as First Manifestation of Essential Thrombocythemia : Report of Six Cases
Stroke,
August 1, 1995;
26(8):
1463 - 1466.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Brenner, A. Nagler, I. Tatarsky, and M. Hashmonai
Splenectomy in Agnogenic Myeloid Metaplasia and Postpolycythemic Myeloid Metaplasia: A Study of 34 Cases
Arch Intern Med,
November 1, 1988;
148(11):
2501 - 2505.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. VALLA, N. CASADEVALL, C. LACOMBE, B. VARET, E. GOLDWASSER, D. FRANCO, J.-N. MAILLARD, E. A. PARIENTE, M. LEPORRIER, B. RUEFF, et al.
Primary Myeloproliferative Disorder and Hepatic Vein Thrombosis: A Prospective Study of Erythroid Colony Formation In Vitro in 20 Patients with Budd-Chiari Syndrome
Ann Intern Med,
September 1, 1985;
103(3):
329 - 334.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. I. SCHAFER
The Hypercoagulable States
Ann Intern Med,
June 1, 1985;
102(6):
814 - 828.
[Abstract]
[PDF]
|
|
|
|
|
